Our QMS enables continuous organizational and process improvement by incorporating a set of coordinated activities designed to direct and control quality operations. These activities include:
Our QMS is based upon the standards set forth in Good Clinical Practices (GCP), College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA).
CAP | CAP Accreditation in 2017 |
CLIA | CLIA Certified since 2010 |
GCP | Q2 Solutions maintains a QMS that is compliant to the applicable Good Clinical Practices for clinical and genomic testing conducted. |
NYS | NYS Certified in 2018 |
To ensure data quality, we monitor several QC metrics and incorporate controls during sample processing. These practices are required as part of our CLIA compliant programs. They are also recommended in voluntary genomic data submissions to the FDA and are recognized best practices. Our efforts promote standardization initiatives including the External RNA Control Consortium (ERCC), MicroArray Quality Control (MAQC) and Sequencing Quality Control (SEQC) Consortiums.
Interferon gamma (IFN) ELISpot and FluoroSpot are widely used immune monitoring assays to detect functional cell responses in clinical studies. Recognized for their importance in vaccine development...
In this episode, Dr. Monika Lamba, a pathologist from Q2 Solutions, discusses the transformative role of digital pathology in clinical trials. Despite its origins aiming to streamline trials, it's...
With emerging and re-emerging infectious diseases, the development of new anti-infectives and vaccines presents many challenges. Q2 Solutions understands these challenges in vaccine development. Our...